The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
As India celebrating its 80th Independence Day in 2026, there are many historical events that…
India’s National Anthem “Jana Gana Mana” is one of the most important national symbols of…
The Indian Independence Act 1947 which was one of the most significant constitutional landmarks in…
The struggle for Indian freedom was waged not just on the streets and in jails…
India celebrates its 80th Independence Day on August 15, 2026, after completing 79 years of…
India’s history since its Independence is a unique story of economic and social development. At…